- Home
- XPEL vs SVRA Comparison
XPEL vs SVRA Comparison
Compare XPEL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | SVRA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 1337 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | XPEL | SVRA |
|---|---|---|
| Price | $46.71 | $5.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $56.00 | $7.33 |
| AVG Volume (30 Days) | 232.9K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | $430.87 |
| P/E Ratio | $25.26 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $26.96 | $1.89 |
| 52 Week High | $55.91 | $7.01 |
Technical Indicators
Market Signals| Indicator | XPEL | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 42.01 |
| Support Level | $31.55 | $4.95 |
| Resistance Level | $55.36 | $6.15 |
| Average True Range (ATR) | 1.60 | 0.29 |
| MACD | 0.15 | -0.09 |
| Stochastic Oscillator | 49.91 | 16.85 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).